文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

碳酸镧与碳酸钙治疗高磷血症对血液透析慢性肾脏病患者心血管事件的影响:LANDMARK随机临床试验

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在伴血管钙化风险的血液透析高磷血症患者中,碳酸镧与碳酸钙相比复合心血管事件无显著差异(HR 1.11,P=0.37),但碳酸镧组心血管死亡和继发性甲状旁腺功能亢进风险增加。

LANDMARK试验为开放标签、盲法终点判定的随机平行组研究,纳入日本273家透析中心的2374例伴高磷血症和至少1项血管钙化风险因素(≥65岁、绝经后、糖尿病)的血液透析慢性肾脏病患者,随机接受碳酸镧(n=1154)或碳酸钙(n=1155),滴定至血清磷3.5–6.0 mg/dL。中位随访3.16年,碳酸镧组复合心血管事件发生率为4.80/100人年,碳酸钙组为4.30/100人年(差值0.50/100人年,95%CI -0.57至1.56;HR 1.11,95%CI 0.88–1.41,P=0.37),无显著差异。碳酸镧组心血管死亡(HR 1.51,95%CI 1.01–2.27,P=0.045)和继发性甲状旁腺功能亢进(HR 1.62,95%CI 1.19–2.20,P=0.002)风险增加。作者认为事件率较低,结果可能不适用于风险更高的患者。

要点

  • 在伴血管钙化风险的血液透析高磷血症患者中,碳酸镧与碳酸钙相比复合心血管事件无显著差异(HR 1.11,95%CI 0.88–1.41,P=0.37)。
  • 碳酸镧组心血管死亡风险增加(HR 1.51,95%CI 1.01–2.27,P=0.045;差值0.61/100人年,95%CI 0.02–1.21)。
  • 碳酸镧组继发性甲状旁腺功能亢进风险增加(HR 1.62,95%CI 1.19–2.20,P=0.002;差值1.34/100人年,95%CI 0.49–2.19)。
  • 全因死亡(HR 1.10,95%CI 0.88–1.37,P=0.42)和髋部骨折(HR 1.21,95%CI 0.62–2.35,P=0.58)无显著差异。
  • 碳酸镧组不良事件282例(25.7%),碳酸钙组259例(23.4%);作者认为事件率低,结果可能不适用于风险更高的患者。

适用人群与场景

  • 纳入:日本273家血液透析中心的慢性肾脏病血液透析患者,伴高磷血症和至少1项血管钙化风险因素(≥65岁、绝经后、糖尿病)。
  • 场景:血液透析设施。

诊断标准与关键阈值

  • 血管钙化风险因素:≥65岁、绝经后、糖尿病,满足至少1项。
  • 滴定目标:血清磷水平维持在3.5 mg/dL至6.0 mg/dL之间。

处置流程与药物剂量

  • 碳酸镧组(n=1154):接受碳酸镧,剂量滴定至血清磷3.5–6.0 mg/dL(原文未给出起始剂量和给药频次)。
  • 碳酸钙组(n=1155):接受碳酸钙,剂量滴定至血清磷3.5–6.0 mg/dL(原文未给出起始剂量和给药频次)。

研究设计与关键结果

  • 研究设计:开放标签、随机、平行组临床试验,盲法终点判定;日本273家血液透析设施;2011年11月至2014年7月入组,2018年6月随访结束。
  • 样本量:2374例随机(碳酸镧组n=1154,碳酸钙组n=1155);2309例纳入分析(中位年龄69岁,女性40.5%),1851例(80.2%)完成试验。
  • 主要终点:复合心血管事件(心血管死亡、非致死性心肌梗死或卒中、不稳定型心绞痛、短暂性脑缺血发作、心力衰竭或室性心律失常住院);碳酸镧组147/1063例 vs 碳酸钙组134/1072例(发生率4.80 vs 4.30/100人年;差值0.50/100人年,95%CI -0.57至1.56;HR 1.11,95%CI 0.88–1.41,P=0.37),中位随访3.16年。
  • 全因死亡:差值0.43/100人年(95%CI -0.63至1.49);HR 1.10(95%CI 0.88–1.37),P=0.42。
  • 髋部骨折:差值0.10/100人年(95%CI -0.26至0.47);HR 1.21(95%CI 0.62–2.35),P=0.58。
  • 心血管死亡:差值0.61/100人年(95%CI 0.02–1.21);HR 1.51(95%CI 1.01–2.27),P=0.045。
  • 继发性甲状旁腺功能亢进:差值1.34/100人年(95%CI 0.49–2.19);HR 1.62(95%CI 1.19–2.20),P=0.002。
  • 不良事件:碳酸镧组282例(25.7%),碳酸钙组259例(23.4%)。

证据类型、等级与局限

  • 证据类型:随机对照试验(开放标签、盲法终点判定)。
  • 局限:作者指出事件率较低,研究结果可能不适用于风险更高的患者。

对床旁实践的改变

  • 在伴血管钙化风险的血液透析高磷血症患者中,碳酸镧与碳酸钙相比未能显著减少复合心血管事件,且碳酸镧组心血管死亡和继发性甲状旁腺功能亢进风险增加。
  • 作者认为事件率低,结果可能不适用于风险更高的患者。

指南或共识出处

  • 临床试验注册:ClinicalTrials.gov Identifier: NCT01578200;UMIN Clinical Trial Registry Identifier: UMIN000006815。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events.

OBJECTIVE: To determine whether lanthanum carbonate reduces cardiovascular events compared with calcium carbonate in patients with hyperphosphatemia at risk of vascular calcification undergoing hemodialysis.

DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized, parallel-group clinical trial with blinded end point adjudication performed in 2374 patients with chronic kidney disease from 273 hemodialysis facilities in Japan. Eligible patients had hyperphosphatemia and 1 or more risk factors for vascular calcification (ie, ≥65 years, postmenopausal, diabetes). Enrollment occurred from November 2011 to July 2014; follow-up ended June 2018.

INTERVENTIONS: Patients were randomized to receive either lanthanum carbonate (n = 1154) or calcium carbonate (n = 1155) and titrated to achieve serum phosphate levels of between 3.5 mg/dL and 6.0 mg/dL.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite cardiovascular event (cardiovascular death, nonfatal myocardial infarction or stroke, unstable angina, transient ischemic attack, or hospitalization for heart failure or ventricular arrhythmia). Secondary outcomes included overall survival, secondary hyperparathyroidism-free survival, hip fracture-free survival, and adverse events.

RESULTS: Among 2309 randomized patients (median age, 69 years; 40.5% women), 1851 (80.2%) completed the trial. After a median follow-up of 3.16 years, cardiovascular events occurred in 147 of 1063 patients in the lanthanum calcium group and 134 of 1072 patients in the calcium carbonate group (incidence rate, 4.80 vs 4.30 per 100 person-years; difference 0.50 per 100 person-years [95% CI, -0.57 to 1.56]; hazard ratio [HR], 1.11 [95%, CI, 0.88 to 1.41], P = .37). There were no significant differences in all-cause death (difference, 0.43 per 100 person-years [95% CI, -0.63 to 1.49]; HR, 1.10 [95% CI, 0.88 to 1.37]; P = .42) or hip fracture (difference, 0.10 per 100 person-years [95% CI, -0.26 to 0.47]; HR, 1.21 [95% CI, 0.62 to 2.35]; P = .58). The lanthanum carbonate group had an increased risk of cardiovascular death (difference, 0.61 per 100 person-years [95% CI, 0.02 to 1.21]; HR, 1.51 [95% CI, 1.01 to 2.27]; P = .045) and secondary hyperparathyroidism (difference, 1.34 [95% CI, 0.49 to 2.19]; HR, 1.62 [95% CI, 1.19 to 2.20]; P = .002). Adverse events occurred in 282 (25.7%) in the lanthanum carbonate group and 259 (23.4%) in the calcium carbonate groups.

CONCLUSIONS AND RELEVANCE: Among patients undergoing hemodialysis with hyperphosphatemia and at least 1 vascular calcification risk factor, treatment of hyperphosphatemia with lanthanum carbonate compared with calcium carbonate did not result in a significant difference in composite cardiovascular events. However, the event rate was low, and the findings may not apply to patients at higher risk.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01578200; UMIN Clinical Trial Registry Identifier: UMIN000006815.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ogata H, Fukagawa M, Hirakata H, et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA. 2021. PMID: 34003226. doi:10.1001/jama.2021.4807

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。